A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC) Meeting Abstract

  

Authors:	Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; Jafri, N.; Korte, S.; Lipson, B.; Yunus, F.; Tanvetyanon, T.; Smith-Marrone, S.; Ng, K. K.; Xiao, H.; Haque, S.; Pfister, D. G.
Abstract Title:	A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Meeting Title:	47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	29
Issue:	15 Suppl.
Meeting Dates:	2011 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2011-05-20
Language:	English
ACCESSION:	WOS:000208880301704
DOI:	10.1200/jco.2011.29.15_suppl.5563
PROVIDER:	wos
Notes:	Meeting Abstract: 5563 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141425